Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial

• Published in: JAMA dermatology (Chicago, Ill.) Vol. 158; no. 12; p. 1357
• Main Authors: Bitar, Carole, Ninh, Thien, Brag, Katherine, Foutouhi, Soraya, Radosta, Stella, Meyers, Jade, Baddoo, Melody, Liu, Delong, Stumpf, Brittany, Harms, Paul W, Saba, Nakhle S, Boh, Erin
• Format: Journal Article
• Language: English
• Published: United States 01.12.2022
• Subjects: Dermatomyositis - chemically induced; Dermatomyositis - drug therapy; Female; Humans; Middle Aged; Severity of Illness Index; Skin; Thalidomide; Treatment Outcome
• ISSN: 2168-6084
• DOI: 10.1001/jamadermatol.2022.3917

Cutaneous disease in dermatomyositis has no standardized treatment approach and so presents a challenging task for patients and clinicians. To study the efficacy and safety of apremilast as an add-on therapy in patients with recalcitrant cutaneous dermatomyositis. This phase 2a, open-label, single-arm nonrandomized controlled trial was conducted at a single center from June 2018 to June 2021. Participants were 8 patients with recalcitrant cutaneous dermatomyositis, defined by a cutaneous disease activity severity index (CDASI) score greater than 5 despite treatment with steroids, steroid-sparing agents, or both. Data were analyzed from June 2018 to June 2021. Apremilast 30 mg orally twice daily was added to ongoing treatment regimens. The primary outcome was the overall response rate (ORR) at 3 months. Key secondary outcomes were the safety and toxicity of apremilast and the durability of response at 6 months. The CDASI, muscle score, dermatology life quality index (DLQI), and depression assessments were performed at baseline and regularly until month 7. Skin biopsies were performed at baseline and 3 months after apremilast (defined as 3 months into active apremilast therapy) and tested for gene expression profiling and immunohistochemical stains. Adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0. Among 8 patients with recalcitrant cutaneous dermatomyositis (all women; mean [SD] age, 54 [15.9] years), a response was found at 3 months after apremilast among 7 patients (ORR, 87.5%). The mean (SD) decrease in CDASI was 12.9 (6.3) points at 3 months (P < .001). Apremilast was well tolerated, with no grade 3 or higher adverse events. Sequencing of RNA was performed on skin biopsies taken from 7 patients at baseline and at 3 months after therapy. Appropriate negative (ie, no primary antibody) and positive (ie, tonsil and spleen) controls were stained in parallel with each set of slides studied. Of 39 076 expressed genes, there were 195 whose expression changed 2-fold or more at P < .01 (123 downregulated and 72 upregulated genes). Gene set enrichment analysis identified 13 pathways in which apremilast was associated with downregulated expression, notably signal transducers and activators of transcription 1 (STAT1), STAT3, interleukin 4 (IL-4), IL-6, IL-12, IL-23, interferon γ (IFNγ), and tumor necrosis factor α (TNFα) pathways. In immunohistochemical staining, there was a mean (SD) decrease in phosphorylation levels STAT1 (22.3% [28.3%] positive cells) and STAT3 (13.4% [11.6%] positive cells) at the protein level, a downstream signaling pathway for the downregulated cytokines. These findings suggest that apremilast was a safe and efficacious add-on treatment in recalcitrant dermatomyositis, with an overall response rate of 87.5% and associations with downregulation of multiple inflammatory pathways. ClinicalTrials.gov Identifier: NCT03529955.